Лекарственно-индуцированный острый канальцевый некроз

36. Ramachandran P, Morcus R, Tahir M, Onukogu I, Spinowitz B, Wang JC. Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature. Journal of Medical Case Reports. 2018;(12):303.

37. Nagai K, Ono H, Matsuura M, Hann M, Ueda S, Yoshimoto S, Tamaki M, Murakami T, Abe H, Ishikura H, Doi T. Progressive renal insufficiency related to ALK inhibitor, alectinib. Oxford Medical Case Reports. 2018: (4), 130-133.

38. Szeto CC, Chow kM. Nephrotoxicity related to new therapeutic compounds. Renal Failure. 2005;27(3):329-33.

39. Palacios-Martinez D, Garcia-Alvarez JC, Montero-Santamaria N, Villar-Ruiz OP, Ruiz-Garcia A, Diaz-Alonso RA. Macrocytic anemia and thrombocytopenia induced by orlistat. International Journal of Endocrinology andMetabolism. 2013;11(4):e6721.

40. Karamadoukis L, Shivashankar GH, Ludeman L, Williams AJ. An unusual complication of treatment with orlistat. Clinical Nephrology. 2009; 71(4):430-432.

41. Sevillano AM, Diaz M, Caravaca-Fontan F, Barrios C, Bernis C, Cabrera J, Calvino J, Castillo L, Cobelo C, Delgado-Mallйn P, Espinosa M, Fernandez-Juarez G, Fernandez-Reyes MJ, Garcia-Osuna R, Garcia P, Goicoechea M, Gonzalez-Cabrera F, Guzman DA, Heras M, MartinReyes G, Martinez A, Olea T, Pena JK, Quintana LF, Rabasco C, Revuelta KL, Rodas L, Rodriguez-Mendiola N, Rodriguez E, Miguel LS, Sanchez de la Nieta MD, Shabaka A, Sierra M, Valera A, Velo M, Verde E, Ballarin J, Noboa O, Juan Moreno JA, Gutiйrrez E, Praga E, Spanish Group for the Study of Glomerular Diseases (GLOSEN).

IgA Nephropathy in Elderly Patients. Clinical Journal of American Society Nephrology. 2019;14(8):1183-1192.

42. Munawar T, Ibe U, Jiwa N, Raissi S. Renal cholesterol crystal embolism in the setting of warfarin use. BMJ Case Reports. 2019;12(8):e230314.

43. Brodsky SV, Mhaskar NS, Thiruveedi S, Dhingra R, Reuben SC, Calomeni E, Ivanov I, Satoskar A, Hemminger J, Nadasdy G, Hebert L, Rovin B, Nadasdy T. Acute kidney injury aggravated by treatment initiation with apixaban: Another twist of anticoagulant-related nephropathy. Kidney Research and Clinical Practice. 2017;36(4):387-392.

44. Al Shohaib S, Raweily E. Acute tubular necrosis due to captopril. American Journal of Nephrology. 2000;20(2):149-152.

45. American Medical Association. AMA Drug Evaluations Annual 1991. Chicago, IL: American Medical Association. 1991. 1766 p.

46. Gilman AG, Rall TW, Nies AS, Taylor P. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: Pergamon Press;1990. 1222 p.

47. Bruneel F, Gachot B, Wolff M, Rйgnier B, Danis M, Vachon F. Fiиvre bilieuse hйmoglobinurique [Blackwater fever]. Presse Med. 2002;31(28):1329-1334.

48. Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Morales AI, Macias-Nunez JF, Lopez-Novoa JM. Effects of deferasirox on renal function and renal epithelial cell death. Toxicology Letters. 2011;203(2):154-161.

49. Oda K, Katayama K, Tanoue A, Murata T, Hirota Y, Mizoguchi S, Hirabayashi Y, Ito T, Ishikawa E, Dohi K, Ito M. Acute kidney injury due to thin basement membrane disease mimicking Deferasirox nephrotoxicity: a case report. BMC Nephrology. 2018;19(1):363.

50. Leroy F, Bridoux F, Abou-Ayache R, Belmouaz S, Desport E, Thierry A, Bauwens M, Touchard G. Nйcrose corticale rйnale bilatйrale induite par la quinine [Quinine-induced renal bilateral cortical necrosis]. Nйphrologie and Thйrapeutique. 2008;4(3):181-186.

51. Usui J, Glezerman IG, Salvatore SP, Chandran CB, Flombaum CD, Seshan SV. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Human Pathology. 2014;45(9):19181927.

52. Sharbaf FG, Farhangi H, Assadi F. Prevention of Chemotherapy-Induced Nephrotoxicity in Children with Cancer. International Journal of Preventive Medicine. 2017; (8):76.

53. Ward FL, John R, Bargman JM, McQuillan RF. Renal Tubular Toxicity Associated With Rosuvastatin Therapy. American Journal of Kidney Diseases. 2017;69(3):473476.

54. Sawada A, Kawanishi K, Morikawa S, Morikawa S, Nakano T, Kodama M, Mitobe M, Taneda S, Koike J, Ohara M, Nagashima Y, Nitta K, Mochizuki T. Biopsy-proven vancomycin-induced acute kidney injury: a case report and literature review. BMC Nephrology. 2018;19(1):72.

55. Leowattana W. Antiviral Drugs and Acute Kidney Injury (AKI). Infectious Disorders Drug Targets. 2019; 19(4):375-382.

56. Сивак КВ. Механизмы нефропатологии токсического генеза. Патогенез. 2019; 17(2): 16-29. [Sivak KV. Mechanisms of nephropathology of toxic genesis. Pathogenesis. 2019; 17(2): 16-29. (In Russian)]

57. Decloedt E, Maartens G. Drug-induced renal injury. Journal of Renal Injury Prevention. 2011; 4(3): 57-60.

58. Yoshiyama Y, Yazaki T, Wong PC, Beauchamp D, Kanke M. The effect of fosfomycin on glycopeptide antibiotic-induced nephrotoxicity in rats. Journal of Infection and Chemotherapy. 2001; 7(4): 243-246.

59. Le Moyec L, Racine S, Le Toumelin P, Adnet F, Larue V, Cohen Y, Leroux Y, Cupa M, Hantz E. Aminoglycoside and glycopeptide renal toxicity in intensive care patients studied by proton magnetic resonance spectroscopy of urine. Critical Care Medicine. 2002; 30(6): 1242-1245.

60. Saunders DA, Begg EJ, Kirkpatrick CMJ, Yeo J, Graham GG, Bailey RR. Measurement of total phospholipids in urine of patients treated with gentamicin. British Journal of Clinical Pharmacology. 1997; 43(4): 435-440.

61. Walker PD, Barri Y, Shah SV. Oxidant Mechanisms in Gentamicin Nephrotoxicity. Renal Failure. 1999; 21(3-4): 433-442.

62. Jamshidzadeh A, Heidari R, Mohammadi-Samani S, Azarpira N, Najbi A, Jahani P, Abdoli N. A comparison between the nephrotoxic profile of gentamicin and gentamicin nanoparticles in mice. Journal of Biochemical and Molecular Toxicology. 2015; 29(2): 57-62.

63. Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Therapeutic Advances in Endocrinology and Metabolism. 2016; 7(3): 136-147.

64. Campos MAA, de Almeida L, Grossi M, Tagliati

C. In vit ro evaluation of biomarkers of nephrotoxicity through gene expression using gentamicin. Journal of Biochemical and Molecular Toxicology. 2018; 32(9): e22189.

65. Vandewalle A, Farman N, Morin JP, Fillastre JP, Hatt PY, Bonvalet JP, with the technical assistance of Gastineau M, Wanstok F. Gentamicin incorporation along the nephron: autoradiographic study on isolated tubules. Kidney International. 1981; (19):529-39

66. Appelkvist EL, Soderstrom M, Nassberger L, Damberg C, Dallner G, DePierre JW Characterization of the lipid and protein contents of myelin bodies isolated from the renal cortex of gentamicin-treated rats. Biochemical and Biophysical Research Communications. 1991; (181):894-901

67. Hosohata K. Role of Oxidative Stress in Drug-Induced Kidney Injury. International Journal of Molecular Sciences. 2016; (17): 1826.

68. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Annals of Internal Medicine. 1984; (100):352-7.

69. Oliveira JFP, Silva CA, Barbieri CD, Oliveira GM, Zanetta DMT, Burdmann EA. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care unit. Antimicrobial Agents and Chemotherapy. 2009; (53):2887-91.

70. Picard W, Bazin F, Clouzeau В, Bui HN, Soulat M, Guilhon E, Vargas F, Hilbert G, Bouchet S, Gruson D, Moore N, Boyer A. Propensity-based study aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock. Antimicrobial Agents and Chemotherapy. 2014; (58):7468-74.

71. Herget-Rosenthal S, Poppen D, Hьsing J, Marggraf G, Pietruck F, Jakob HG, Philipp Th, Kribben A. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clinical Chemistry. 2004; (50):552-8.

72. Постников СС, Грацианская АН, Костылева МН. Лекарственные поражения почек. Педиатрия. 2016; 95(4):67-173. [Postnikov SS, Gracianskaja AN, Kostyleva MN. Drug-induced kidney injury. Pediatria. 2016; 95(4):67-173. (In Russian)]

73. Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Critical Care Medicine. 2008;:216-23.

74. Ronco C, Bellomo R, Kellum JA, Ricci Z. Critical Care Nephrology. Philadelphia: Elsevier; 2019.1456 p.

75. Rocha Pn, Kobayashi CD, de Carvalho AL, de Oliveira dos Reis C, Santos BM, Glesby MJ. Incidence, predictors, and impact of hospital mortality on amphotericin В nephrotoxicity defined using newer acute kidney injury diagnostic criteria. Antimicrobial Agents and Chemotherapy. 2015; (59):4759-69.

76. Chavez-Iniguez JS, Medina-Gonzalez R, Aguilar-Parra L, Torres-Vazquez EJ, Maggiani-Aguilera P, Cervantes-Pйrez E, Garcia-Garcia G. Oral acyclovir induced hypokalemia and acute tubular necrosis a case report. BMC Nephrology. 2018. (19):324.

77. Yildiz C, Ozsurekci Y, Gucer S, Cengiz AB, Topaloglu R. Acute kidney injury due to acyclovir. CEN Case Reports. 2013;2(1):38-40.

78. Fleischer R, Johnson M. Acyclovir nephrotoxicity: a case report highlighting the importance of prevention, detection, and treatment of acyclovir-induced nephropathy. Case Reports in Medicine. 2010: 602783.

79. Ryan L, Heed A, Foster J, Valappil M, Schmid ML, Duncan CJA. Acute kidney injury (AKI) associated with intravenous acyclovir in adults: incidence and risk factors in clinical practice. International Journal of Infectious Diseases. 2018; (74): 97-99.

80. Lu H, Han YJ, Xu JD, Xing WM, Chen J. Proteomic characterization of acyclovir-induced nephrotoxicity in a mouse model. PLoS One. 2014; 9(7): e103185.

81. Mason W, Nickols H. Crystalluria from acyclovir use. The New England Journal of Medicine. 2008;(358): e14.

82. Mazer M, Perrone J. Acetaminophen-Induced Nephrotoxicity: Pathophysiology, Clinical Manifestations, and Management. Journal of Medical Toxicology. 2008; 4(1): 2-6.

83. Blakely P, McDonald BR. Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. Journal of the American Society of Nephrology. 1995; (6):48-53.

84. Von Mach MA, Hermanns-Clausen M, Koch I, Hengstler JG, Lauterbach M, Kaes J, Weilemann LS. Experiences of a poison center network with renal insufficiency in acetaminophen overdose: an analysis of 17 cases. Clinical Toxicology. 2005; (43):31-37.

85. Sciskalska M, Sliwinska-Mosson M, Podawacz M, Sajewicz W, Milnerowicz H. Mechanisms of interaction of the N-acetyl-p-aminophenol metabolites in terms of nephrotoxicity. Drug and Chemical Toxicology. 2015; 38(2):121-125.

86. Boutis, K, Shannon M. Nephrotoxicity after acute severe acetaminophen poisoning in adolescents. Clinical Toxicology. 2001; (39):41-445.

87. Mour G, Feinfeld DA, Caraccio T, McGuigan M. Acute renal dysfunction in acetaminophen poisoning. Renal Failure. 2005; (27):381-383.

88. Almeida AF. Drug-Induced Renal Disease - Prevention Strategies. Journal of Medicine Update. 2005.:637-641.

89. Lagrange JL, Medecin B, Etienne MC, Pivot X, Cassuto-Viguier E, Renйe N, Thyss A, Ferrero JM, Otto J, Franзois E, Milano G. Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors. Pharmacotherapy. 1997; (17):1246-53.

90. Reece PA, Stafford I, Russell J, Khan M, Gill PG. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable plantium plasma levels and nephrotoxicity. Journal of Clinical Oncology. 1987; (5):304-9.

91. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin Nephrotoxicity: A Review. The American Journal of the Medical Sciences. 2007; 334(2): 115-124.

92. Safirstein R, Winston J, Golstein M, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity. American Journal of Kidney Diseases. 1986; (5):356-67.

93. Briguori C, Manganelli E, Scarpato F, Elia PP, Golia B, Riviezzo G, Lepore S, Librera M, Villari B, Colombo A, Ricciardelli B. Acetylcysteine ccr trast agent-associated nephropathy. Journal of the American College of Cardiology. 2002; (40):298-303.

94. Lau AH. Apoptosis induced by cisplatin nephrotoxic injury. Kidney International. 1999; (56):1295-8.

95. Malyszko J, Kozlowska K, Kozlowski L, Malyszko J. Nephrotoxicity of anticancer treatment. Nephrology Dialysis Transplantation. 2017; 32(6):924-36.

96. Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-term renal outcomes after cisplatin treatment. Clinical Journal of the American Society of Nephrology. 2016; 11(7):1173-9.

97. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Safety. 2001; (24):19-38

98. Gronroos M, Chen M, Jahnukainen T, Capitanio A, Aizman RI, Celsi G. Methotrexate induces cell swelling and necrosis in renal tubular cells. Pediatric Blood and Cancer. 2006; 46(5):624-629.

99. Green MR, Chowdhary SA, Chalmers LM, Lombardi KM, Chamberlain MC. High-dose methotrexate complicated by acute tubular necrosis: a case report. Therapy. 2006. 3(4), 495-497.

100. Krzemien G, Szmigielska A, Bieroza I, Roszkowska-Blaim M. Zlozona etiologia ostrej niewydolnosci nerek u noworodka [Complex etiology of acute renal failure in a newborn]. Polski Merkuriusz Lekarski. 2008; 24 (4):138- 140.

101. Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. The Oncologist. 2016; 21(12):1471-82.

102. Perazella MA. Update on the renal effects of anticancer agents. Journal of Onco-Nephrology. 2017; 1(3):170- 178.

103. Ensergueix G, Karras A. Nйphrotoxicitй de l'ifosfamide [Ifosphamide nephrotoxicity]. Nйphrologie and Thйrapeutique. 2018; 14(1):125-131.

104. Skinner R, Pearson AD, Price L, Coulthard MG, Craft AW Nephrotoxicity after ifosfamide. Archives of Diseases in Childhood. 1990; 65(7): 732-8.

105. Leem AY, Kim HS, Yoo BW, Kang BD, Kim MH, Rha SY, Kim HS. Ifosfamide-induced Fanconi syndrome with diabetes insipidus. The Korean Journal of Internal Medicine. 2014; 29(2): 246-9.

106. Дорохина ЕИ, Магомедова АУ, Куликов СМ, Бирюкова ЛС, Кременецкая АМ, Воробьев АИ, Кравченко СК. Отдаленная нефротоксичность высокодозной химиотерапии по модифицированной программе NHL-BFM-90 у взрослых больных диффузной В-крупноклеточной лимфомой. Гематология и трансфузиология. 2016; 61(4): 177-183. [Dorohina EI, Magomedova AU, Kulikov SM, Birjukova LS, Kremeneckaja AM, Vorob'ev AI, Kravchenko SK. Late nephrotoxicity of modified program NHL-BFM-90 in adult patients poor prognosis of diffuse large B-cell lymphoma. Russian Journal of Hematology and Transfusiology. 2016; 61(4): 177-183. (In Russian)]

107. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney International. 2008; 74(11):1385- 1393.

108. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. The New England Journal of Medicine. 2003; (349): 1676-1679.

109. Markowitz GS, Fine PL, Stack JI, Kunis ChL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD. Toxic acute tubular necrosis following treatment with zoledronate. Kidney International. 2003; (64): 281-289.

110. Kanellias N, Gavriatopoulou M, Terpos E, Dimopoulos MA. Management of multiple myeloma bone disease: impact of treatment on renal function. Expert Review of Hematology. 2018; 11(11):881-888.

111. Banerjee D, Asif A, Striker L, Preston R,

Bourgoignie JJ, Roth D. Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity. American Journal of Kidney Diseases. 2003; (41): E18.

112. Smetana S, Michlin A, Rosenman E, Biro A, Boaz M, Katzir Z. Pamidronate-induced nephrotoxic tubular necrosis - a case report. Clinical Nephrology. 2004; (61): 63-67.

113. Rogers MJ, Gordon S, Benford HL,Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphophosphonates. Cancer. 2000; (88): 2961-2978. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and dysfunctional consequences. Annual Review of Pharmacology and Toxicology. 1997; (37): 143-166.

114. Clark EA, King WG, Brugge JS, Symons M, Hynes RO. Integrin-mediated signals regulated by members of the rho family of GTPases. Journal of Cell Biology. 1998; (142): 573-586.

115. Ridley AJ, Paterson HF, Johnnston CL, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 1992; (70): 401-410.

116. Zhang D, Udagawa N, Nakamura I, Murakami H, Saito S, Yamasaki K, Shibasaki Y, Morii N, Narumiya S, Takahashi N. The small GTP-binding protein rho p21 is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. Journal of Cell Science. 1995; (108): 2285-2292.

117. Lьhe A, Kьnkele KP, Haiker M, Schad K, Zihlmann Ch, Bauss F, Suter L, Pfister Th. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl disphosphate (FPP) synthase in the kidney: Implications for renal safety. Toxicology in Vitro. 2008; (22): 899-909.

118. Rogers MJ, Ji X, Russell RG, Blackburn GM, Williamson MP, Bayless AV, Ebetino FH, Watts DJ. Incorporation ofbisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochemical Journal. 1994; (303): 303-311.

119. Hiroi-Furuyama E, Kameda T, Hiura K, Mano H, Miyazawa K, Nakamaru Y, Watanabe-Mano M, Okuda N, Shimada J, Yamamoto Y, Hakeda Y, Kumegawa M. Etidronate (EHDP) inhibits osteoclastic bone resorption, promotes apoptosis, and disrupts actin rings in isolate- mature osteoclasts. Calcified Tissue International. 1999; (64): 219-223.

120. Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. The Oncologist. 2005; (19): 3-7.

Размещено на Allbest.ru